Novartis moves into Japan's vaccine market with Takeda deal
This article was originally published in Scrip
Executive Summary
Novartis is entering Japan's vaccine sector through an alliance with Takeda for the Haemophilus influenzae type B (Hib) product Vaxem-Hib.